Expect closer supervision of US biologics settlements in wake of Humira ‘reverse payment’ concerns

Two US senators have called on the Federal Trade Commission (FTC) to examine patent settlements involving biologic and biosimilar producers, echoing calls from patient advocacy groups. Raising particular concerns about AbbVie’s recent high-profile…


Get unlimited access to all IAM content